Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 1:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 20,991 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immune System Disorders Clear all
Terminated Phase 2 Interventional Results available

A Study of RO7123520 to Evaluate the Safety and Efficacy in Participants With Moderately To Severely Active Rheumatoid Arthritis (RA) Who Are Inadequately Responding to Anti-Tumor Necrosis Factor (TNF)-Alpha Therapy

NCT03001219
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Anti-TNF-alpha, Methotrexate, Placebo, RO7123520
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
32
States / cities
Anniston, Alabama • Glendale, Arizona • Mesa, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2020 · Synced Oct 21, 2026, 1:03 AM EDT
Completed Not applicable Interventional Results available

AdheRence to Inhaled Corticosteroids in Asthma

NCT03769519
View directory record Official record
Conditions
Medication Adherence, Asthma
Interventions
ARICA
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 17, 2021 · Synced Oct 21, 2026, 1:03 AM EDT
Completed Not applicable Interventional Results available

Development of a Behavioral Observer for Type 1 Diabetes Mellitus

NCT01434030
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Focus Group
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
21 Years to 65 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 4, 2014 · Synced Oct 21, 2026, 1:03 AM EDT
Active, not recruiting Phase 1 Interventional

Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma

NCT02659930
View directory record Official record
Conditions
Kaposi Sarcoma
Interventions
liposomal doxorubicin, pomalidomide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 21, 2026, 1:03 AM EDT
Terminated Phase 2 Interventional Results available

Study of Daxdilimab (HZN-7734) in Participants With Active Proliferative Lupus Nephritis (LN)

NCT05540665
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Daxdilimab, Placebo (Normal Saline)
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
5
States / cities
Birmingham, Alabama • San Dimas, California • Syracuse, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Oct 21, 2026, 1:03 AM EDT
Terminated Not applicable Interventional

Effects of Behavioral Interventions on Mechanisms of Pain Regulation and Hedonic Regulation

NCT02935465
View directory record Official record
Conditions
Chronic, Non-neuropathic Back Pain
Interventions
Mindfulness-Oriented Recovery Enhancement (MORE), Support Group
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
21 Years to 60 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 6, 2020 · Synced Oct 21, 2026, 1:03 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Development and Evaluation of a Virtual Reality Tool for At-Risk Trauma-Exposed Young People

NCT05816083
View directory record Official record
Conditions
Substance Use Disorders, HIV Infections
Interventions
Virtual Reality Tool
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
15 Years to 30 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 21, 2026, 1:03 AM EDT
Completed Not applicable Interventional Results available

Safety and Efficacy of Initializing the Control-IQ Artificial Pancreas System Using Total Daily Insulin

NCT03804983
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Hybrid Closed Loop (HCL), Control-IQ with MyTDI
Device
Lead sponsor
University of Virginia
Other
Eligibility
12 Years to 18 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 1, 2024 · Synced Oct 21, 2026, 1:03 AM EDT
Completed Phase 1 Interventional

Effect of Talactoferrin in Adults With Non-Small Cell Lung Cancer

NCT00923741
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Talactoferrin, Apheresis
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Oct 21, 2026, 1:03 AM EDT
Completed Phase 1 Interventional

CC-5013 in Treating Patients With Cancer That Has Not Responded to Previous Therapy

NCT00031941
View directory record Official record
Conditions
Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
lenalidomide
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Oct 21, 2026, 1:03 AM EDT
Enrolling by invitation No phase listed Observational

Tornier HRS (Humeral Reconstruction System) Study (REVIVE)

NCT05500066
View directory record Official record
Conditions
Rheumatoid Arthritis, Osteoarthritis Shoulder, Fractures Humerus, Avascular Necrosis, Correction of Functional Deformity, Traumatic Arthritis, Revision of Other Devices if Sufficient Bone Stock Remains, Rotator Cuff Tears
Interventions
Tornier HRS (HUMERAL RECONSTRUCTION SYSTEM) shoulder system
Device
Lead sponsor
Stryker Trauma and Extremities
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2036
U.S. locations
4
States / cities
Denver, Colorado • Bradenton, Florida • Tampa, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 21, 2026, 1:03 AM EDT
Completed Phase 3 Interventional Results available

Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation

NCT01371656
View directory record Official record
Conditions
Acute Leukemias of Ambiguous Lineage, Bacterial Infection, Diarrhea, Fungal Infection, Musculoskeletal Complications, Neutropenia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Interventions
levofloxacin
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
6 Months to 21 Years
Enrollment
624 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
78
States / cities
Little Rock, Arkansas • Downey, California • Duarte, California + 65 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Oct 21, 2026, 1:03 AM EDT
Completed Phase 1 Interventional

Comparison of the Safety and Pharmacokinetics of Two SAR153191 (REGN88) Drug Products in Rheumatoid Arthritis Patients

NCT01328522
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
SAR153191 (REGN88)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
4
States / cities
Beverly Hills, California • Ocala, Florida • Duncansville, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2011 · Synced Oct 21, 2026, 1:03 AM EDT
Not yet recruiting Phase 4 Interventional Accepts healthy volunteers

NOTRE: Optimizing Long-Acting Pre-Exposure Prophylaxis and Medications for Opioid Use Disorder Interventions in Carceral Settings

NCT06854029
View directory record Official record
Conditions
HIV Infections, Opioid Use Disorder, Incarceration; Lens
Interventions
Cabotegravir Injection, Cabotegravir Pill, Buprenorphine injection, Buprenorphine Pill
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 21, 2026, 1:03 AM EDT
Completed No phase listed Observational Results available

A Study to Understand How Effective is Tofacitinib When Compared to Other Advanced Treatments in Patients With Rheumatoid Arthritis

NCT06418529
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
tofacitinib, tumor necrosis factor inhibitors (TNFi), abatacept, tocilizumab or sarilumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
21,340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Oct 21, 2026, 1:03 AM EDT
Completed Phase 1 Interventional

Islet Transplantation in Type 1 Diabetic Patients

NCT00214253
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Thiazolidinedione
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 31, 2017 · Synced Oct 21, 2026, 1:03 AM EDT
Not listed Phase 4 Interventional

Onset of Action of Advair Hydrofluoroalkane (HFA) 115/21 in Comparison to Symbicort Pressurised Metered-Dose Inhalers (pMDI) 160/4.5 Measured by Impulse Oscillometry (IOS)

NCT00867737
View directory record Official record
Conditions
Asthma
Interventions
Advair HFA MDI 115/21, Symbicort 160/4.5 pMDI
Drug
Lead sponsor
Allergy and Asthma Center of El Paso
Other
Eligibility
12 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Mar 24, 2009 · Synced Oct 21, 2026, 1:03 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene

NCT01875237
View directory record Official record
Conditions
Leukemia, Myeloma, Myeloproliferative Diseases
Interventions
Fludarabine, Melphalan, Alemtuzumab, Stem Cell infusion, Tacrolimus, Mini Methotrexate, G-CSF, Donor Lymphocyte Infusion (DLI), AP1903, Methylprednisolone, Questionnaire
Drug · Procedure · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced Oct 21, 2026, 1:03 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype

NCT02589145
View directory record Official record
Conditions
Lymphoma
Interventions
Lenalidomide, Vorinostat, Gemcitabine, Busulfan, Melphalan, Rituximab, Dexamethasone, Caphosol, Glutamine, Pyridoxine, Enoxaparin, Stem Cell Transplant, Palifermin
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 13, 2019 · Synced Oct 21, 2026, 1:03 AM EDT
Completed No phase listed Observational

Collection of Blood Samples From HIV Infected People

NCT00096772
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
2,502 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
83
States / cities
Mill Valley, California • Oakland, California • San Francisco, California + 32 more
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Oct 21, 2026, 1:03 AM EDT
Recruiting Phase 2 Interventional

Elranatamab in R/R Multiple Myeloma

NCT06138275
View directory record Official record
Conditions
Refractory Multiple Myeloma, Relapse Multiple Myeloma, Multiple Myeloma
Interventions
Elranatamab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 21, 2026, 1:03 AM EDT
Withdrawn Phase 4 Interventional

Velcade for Proliferative Lupus Nephritis

NCT01169857
View directory record Official record
Conditions
Lupus Nephritis, Proteinuria, Hematuria
Interventions
Velcade
Drug
Lead sponsor
The Rogosin Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2012 · Synced Oct 21, 2026, 1:03 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen

NCT00448357
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
rabbit anti-thymocyte globulin (ATG), therapeutic allogeneic lymphocytes, busulfan, fludarabine phosphate, tacrolimus, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, methotrexate
Biological · Drug · Procedure
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 17, 2017 · Synced Oct 21, 2026, 1:03 AM EDT
Completed Phase 2 Interventional Results available

AMD3100 (Plerixafor) Added to a Mobilizing Regimen of Granulocyte-colony Stimulating Factor (G-CSF) to Increase the Number of Peripheral Blood Stem Cells (PBSCs) in Patients With Hodgkin's Disease

NCT00396201
View directory record Official record
Conditions
Hodgkin's Disease
Interventions
G-CSF Plus Plerixafor
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 13, 2014 · Synced Oct 21, 2026, 1:03 AM EDT